Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


COX-2 inhibitor actions

Executive Summary

FDA's drug safety committee will review the agency's actions regarding the safety of COX-2 inhibitors on Feb. 10. Two selective COX-2 non-steroidal anti-inflammatory drugs have been pulled from the market, Merck's Vioxx and Pfizer's Bextra. Pfizer's Celebrex remains on the market (1"The Pink Sheet" Dec. 19, 2005, p. 18). The committee will also receive updates on the Drug Safety Oversight Board and risk management programs for isotretinoin products. The meeting will take place at the Holiday Inn in Gaithersburg, Md., beginning at 8 a.m...

You may also be interested in...

Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study

Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13

Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts